3 Firms Guide Dutch Biotech Startup's $326M SPAC Merger
Cardiovascular disease-focused NewAmsterdam Pharma BV has agreed to go public by merging with special purpose acquisition company Frazier LifeSciences Acquisition Corp. in a deal, guided by three firms, that values the...To view the full article, register now.
Already a subscriber? Click here to view full article